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Mutations in the Glycosylphosphatidylinositol
Gene PIGL Cause CHIME Syndrome
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Shruti Bhide,3 Vincent Cantagrel,4 Joseph G. Gleeson,4 Amy S. Paller,5 Rhonda E. Schnur,6
Sigrid Tinschert,2 Janice Zunich,7 Madhuri R. Hegde,3 and Hudson H. Freeze1,*
CHIME syndrome is characterized by colobomas, heart defects, ichthyosiform dermatosis, mental retardation (intellectual disability),
and ear anomalies, including conductive hearing loss. Whole-exome sequencing on five previously reported cases identified PIGL,
the de-N-acetylase required for glycosylphosphatidylinositol (GPI) anchor formation, as a strong candidate. Furthermore, cell lines
derived from these cases had significantly reduced levels of the two GPI anchor markers, CD59 and a GPI-binding toxin, aerolysin
(FLAER), confirming the pathogenicity of the mutations.CHIME syndrome (MIM 280000), also known as Zunich
neuroectodermal syndrome, is an extremely rare auto-
somal recessive multisystemic disorder clinically character-
ized by colobomas, congenital heart defects, early onset
migratory ichthyosiform dermatosis, mental retardation
(intellectual disability), and ear anomalies, including
conductive hearing loss. Other clinical manifestations
include distinctive facial features, abnormal growth, geni-
tourinary abnormalities, seizures, and feeding difficul-
ties.1 To date, eight cases have been reported, all having
nearly identical phenotypes.
In 2010, Cantagrel et al.2 described a congenital disorder
of glycosylation (CDG) in which individuals with patho-
logical mutations in SRD5A3 (MIM 611715) presented
with CHIME-like features (MIM 612379). Yet individuals
with Classical CHIME as described by Zunich1 lacked
mutations in SRD5A3. We hypothesized that CHIME
syndrome could be a glycosylation disorder on the basis
of the clinical similarity to those individuals identified by
Cantagrel.2
To test this, we obtained DNA samples from six of the
eight previously described cases from five unrelated fami-
lies for the purpose of whole-exome sequencing (WES).
All clinical samples were obtained with proper informed
consent in accordance with the Sanford-BurnhamMedical
Research Institute’s institutional review board consent
guidelines.
To identify the genetic cause of CHIME syndrome,
we performed WES on five of six previously described
cases.3,4 Exome sequences were enriched with the Roche
Nimblegen Seqcap EZ whole-exome Ver 2.0 on an Illumina
HiSeq platform, and the raw data were aligned to hg18.
Analysis employed Agilent’s AVADIS NGS software.
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The Amtotal variants and an average of 3,774 novel variants with
87% of the exome targets having at least 103 coverage
(Table 1).
A sixth case previously described by Tinschert et al.5 was
the only sample analyzed by comparative genomic hybrid-
ization (CGH) array; it showed a 1MBmaternally inherited
deletion on chromosome 17. DNA was isolated from
whole blood with QIAGEN’s DNA blood kit according to
the manufacturer’s protocol (QIAGEN, Hilden, Germany).
Array CGH was performed on Agilent’s SurePrint G3
Human CGH Microarray Kit 2x400K (Design ID 021850,
Agilent, Santa Clara, CA, USA) according to the manufac-
turer’s protocol, except that dyes were used inversely on
sample and reference. An Agilent microarray scanner
provided the raw data that were processed by Feature
Extraction 9.5. Deleted and amplified regions were identi-
fied on Agilent’s Genomic Workbench Standard Edition
5.0.14. Customized CGH array confirmed copy number
variants and familial segregation. Agilent’s eArray platform
had a general probe density of 1 per 200 bp to 1 per 2.5 kb
depending on the size of the variant. The coordinates of
the array result were mapped to hg18.
We focused exome analysis on the 17 genes in this
region (chromosome 17: 15,620,754–16,698,489 hg18) as
likely candidates. We excluded synonymous changes, vari-
ants in dbSNP v133, and variants present in a limited (30)
in-house exome library. All cases had compound heterozy-
gous mutations in only PIGL [RefSeq NM_004278.3]
within that region (Figure 1). Sanger sequencing confirmed
all mutations in PIGL, and carrier status in each available
parent or sibling (family 665 was not available) excluded
de novo events.
PIGL (NP_004269 [MIM 605947]) is an endoplasmic
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Table 1. Summary of WES Statistics for Five CHIME Syndrome Cases
Individual
Average680-2-2 680-2-3 682-2-1 665-3-1 3988
Total number of sequenced reads 53,341,240 54,687,243 47,134,146 117,769,811 121,450,190 78,876,526
Total number of unmapped reads (%) 1,257,149 (2.4%) 765,214 (1.4%) 738,306 (1.6%) 934,246 (0.8%) 988,578 (0.8%) 936,699 (1.2%)
Total number of mapped reads 52,084,091 53,922,029 46,395,840 116,835,565 120,461,612 77,939,827
Percentage Targets with 103 coverage 78 88 85 88 95 87
Percentage Targets with 203 coverage 43 65 59 79 89 67
Total NS-SS-Indels 10,022 12,211 11,921 15,614 12,978 12,549
Novel NS-SS-Indels 2,338 3,211 3,181 7,173 2,966 3,774step of glycosylphosphatidylinositol (GPI) biosynthesis,
the de-N-acetylation of N-acetylglucosaminyl-phosphati-
dylinositol (GlcNAc-PI / GlcN-PI) that occurs on the
cytoplasmic side of the ER.6 Following de-N-acetylation,
glucosaminyl-phosphatidylinositol (GlcN-PI) flips to the
luminal side of the ER where GlcN-PI undergoes further
extensions prior to its transfer to acceptor proteins.7
Aside from a possible founder missense mutation, the
other mutations identified in our six CHIME cases are
predicted to be highly damaging (frameshift, nonsense,
essential splice site, and entire gene deletion) (Table 2).
The c.500T>C (p.Leu167Pro) mutation found in all six
cases is at a highly conserved residue (Table 3) located in
the catalytic domain and predicted by both PolyPhen
and SIFT to be damaging.
Utilizing two large public databases, we found the
heterozygous missense mutation c.500T>C in eight out
of nearly 13,000 alleles. In the National Heart, Lung, and
Blood Institute (NHLBI) Exome Sequencing Project, the
c.500T>C mutation appears at a frequency of 6:10,752
alleles (5,376 genomes; with all six heterozygotes being
of European origin). In the 1000 Genomes database, it
was present at 2:2,188 alleles (1,094 genomes). Given the
relatively rare frequency (<0.1%) and the fact that all six
CHIME cases are of European ancestry, we hypothesized
that c.500T>C was due to a founder mutation.
We compared twomicrosatellite markers, 17xATT (trinu-
cleotide marker) and 19xGT (dinucleotide marker), on
chromosome 17: 15,620,754–16,698,489 (hg18) flanking686 The American Journal of Human Genetics 90, 685–688, April 6, 2PIGL. The c.500T>C missense mutation was tightly linked
with the 17xATT in all CHIME cases with an ATT repeat
size of 22, whereas European controls (16) had a repeat
size of 17 repeats. Furthermore, all CHIME cases had a
19xGT repeat size of 13, whereas the European controls
(15) had a repeat size of 19. These results support linkage
disequilibrium between the c.500T>C allele and allele 22
of the 17xATT and allele 13 of the 19xGT marker (data
not shown).
To confirm that the mutations in PIGL are pathological,
we utilized a primary fibroblast cell line from individual
3988 and an Epstein-Barr virus (EBV)-transformed
lymphoblast cell line from individual 33300 to measure
two separate cell surface GPI-anchor-containing markers,
CD59 and a GPI-binding toxin, aerolysin (FLAER). In
agreement with other proven GPI deficiencies, cells
available from CHIME syndrome cases are also deficient
for both GPI anchor markers (Figure 2). It is important
to note that individual 33300 carries the chromo-
some 17 deletion and c.500T>C mutation, making her
hemizygous for the mutation and proving that it is
pathogenic.
Three inherited genetic disorders were previously identi-
fied in GPI biosynthetic genes: PIGM (MIM 610273), PIGN
(MIM 606097), and PIGV (MIM 610274).8–10 Somatic
mutations in PIGA (MIM 311770) cause paroxysmal
nocturnal hemoglobinuria (MIM 300818), a hematologic
disorder.11 Interestingly, epidermal-specific knockout
of mouse PigA recreates features of human HarlequinFigure 1. Organization of Human PIGL and
Associated Mutations
Schematic representation showing both genomic
and protein organization of human PIGL with
corresponding mutations as well as functional
protein domains including a 20aa transmem-
brane domain (TMD) and the core de-N-acetylase
domain.
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Table 3. Evolutionary Conservation of Leu167
Species Ortholog of Human Leu167
Homo sapiens YAAVRA L HSEGK
Mus musculus YKAVRA L HSGGK
Rattus norvegicus YKAVRA L HSGGK
Danio rerio YKTLSH L ASAGR
Saccharomyces cerevisiae YAAVKK L VDDYA
Gallus gallus YAAVRA L HSEGK
Drosophila melanogaster YAAAS L CLANL
































aSecond mutation not identified; parent DNA unavailable.ichthyosis.12 Mutations in PIGM, encoding the first man-
nosyltransferase, are associated with venous thrombosis
and seizures (MIM 610293).8 Mutations in PIGN, which
encodes the ethanolamine phosphate transferase, cause
multiple congenital anomalies-hypotonia-seizures
syndrome (MIM 614080).9 Deficiencies in PIGV, which
encodes the second mannosyltransferase in GPI forma-
tion, are associated with the hyperphosphatasia mental
retardation syndrome (MIM 239300).10
One clear difference between PIGL deficiency and the
other GPI deficiencies is the magnitude of GPI marker
decrease. Although we have consistently seen a significant
decrease of 2- to 4-fold in both cell lines, the decrease was
less dramatic than those seen in the other PIG defi-
ciencies. One explanation is that the p.Leu167Pro alter-Figure 2. Cell Surface Expression of Total GPI Anchor and CD59
Fluorescence-activated cell sorting analysis for two separate GPI ancho
from individual 3988 and an EBV transformed lymphoblast line from
two normal controls were used. Shown is a representation of the tw
The Amation mildly affects the binding and de-N-acetylation of
the GlcNAc-PI, but GlcN-PI can still be flipped into the
luminal side of the ER. Furthermore, although we show
a link between the p.Leu167Pro alteration and CHIME
syndrome, we cannot exclude the possibility that addi-
tional mutations in PIGL could cause disorders other
than CHIME syndrome.
GPI anchor deficiencies cause remarkable clinical diver-
sity but that is typical of other glycosylation pathways
such as the 38 Congenital Disorders of Glycosylation or
6 a-dystroglycanopathies.13 Hypomorphic alleles predom-
inate, and the clinical impact often depends more on
the severity of the mutation than on the specific mutated
gene.14 In conclusion; we analyzed six previously
described CHIME syndrome cases by using a combination
of genetic and biochemical approaches, including CGH
array and WES. We show that mutations in PIGL impair
GPI biosynthesis and are the underlying cause of this
disorder.rmarkers, CD59 and FLAER, were used on a primary fibroblast line
individual 33300 to evaluate GPI anchor levels. In both instances,
o. Dotted lines indicate isotype controls.
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